Revumenib, Revumenib, Placebo for Revumenib tablets, CYTARABINE, IDARUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, Revumenib
SNDX-5613-0710
Phase 3 small_molecule active
Quick answer
Revumenib, Revumenib, Placebo for Revumenib tablets, CYTARABINE, IDARUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, Revumenib for Newly Diagnosed AML with an NPM1 mutation is a Phase 3 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals Inc
- Indication
- Newly Diagnosed AML with an NPM1 mutation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active